Beijing Tiantan Biological Products Corp Ltd
SSE:600161
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
20.5
32.06
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Beijing Tiantan Biological Products Corp Ltd
Beijing Tiantan Biological Products Corp Ltd
Research & Development
Beijing Tiantan Biological Products Corp Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Beijing Tiantan Biological Products Corp Ltd
SSE:600161
|
Research & Development
-¥180.3m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
N/A
|
|
|
Beigene Ltd
HKEX:6160
|
Research & Development
-¥12.5B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
N/A
|
|
|
Innovent Biologics Inc
HKEX:1801
|
Research & Development
-¥2.7B
|
CAGR 3-Years
-10%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
N/A
|
|
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
|
Research & Development
-¥1.1B
|
CAGR 3-Years
-54%
|
CAGR 5-Years
-54%
|
CAGR 10-Years
N/A
|
|
|
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
|
Research & Development
-¥1B
|
CAGR 3-Years
-47%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
|
Imeik Technology Development Co Ltd
SZSE:300896
|
Research & Development
-¥232.4m
|
CAGR 3-Years
-59%
|
CAGR 5-Years
-49%
|
CAGR 10-Years
N/A
|
|
Beijing Tiantan Biological Products Corp Ltd
Glance View
In the bustling heart of China's biotech industry, Beijing Tiantan Biological Products Corp Ltd emerges as a key player in the crucial field of vaccine and blood product innovations. Rooted in the expansive landscape of pharmaceutical development, the company sets its focus on producing essential vaccines—including those for hepatitis B—and blood-derived products such as albumin, immunoglobulin, and coagulation factor. These products play pivotal roles in preventative healthcare and in treating various diseases. Tiantan Bio operates with a robust integration of research and manufacturing expertise, underpinned by a deep commitment to public health advancement. The company continuously seeks to expand its product offerings, refining processes through relentless research and development to meet the demands of both domestic and international markets. Earnings for Tiantan Biological flow primarily from the successful commercialization of its vaccines and blood products. The company establishes strategic partnerships with research institutions and leverages government healthcare policies that favor domestic vaccine consumption to bolster its market position. Tiantan Bio also invests significantly in infrastructure to upscale its production capabilities, responding to the growing demand for its products. Their business model capitalizes on the symbiotic relationship between research innovation and market needs, ensuring a steady stream of revenue through both public procurement and private healthcare partnerships. This strategic orientation not only showcases its influence in the biotech sphere but also reflects its adaptability and foresight in navigating the dynamic landscape of global healthcare challenges.
See Also
What is Beijing Tiantan Biological Products Corp Ltd's Research & Development?
Research & Development
-180.3m
CNY
Based on the financial report for Sep 30, 2024, Beijing Tiantan Biological Products Corp Ltd's Research & Development amounts to -180.3m CNY.
What is Beijing Tiantan Biological Products Corp Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-6%
Over the last year, the Research & Development growth was -82%. The average annual Research & Development growth rates for Beijing Tiantan Biological Products Corp Ltd have been -13% over the past three years , -6% over the past five years .
You don't have any saved screeners yet
